Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety

Sep. 10, 2013

Civitas Therapeutics begins phase IIb study of inhaled levodopa

Sep. 9, 2013

QRxPharma to discuss MoxDuo NDA with FDA prior to refiling

Sep. 9, 2013

Exon-skipping compound PRO-053 begins phase I/II trial for Duchenne muscular dystrophy

Sep. 9, 2013

CP-9531 demonstrates efficacy for multiple sclerosis

Sep. 9, 2013

Reductions in rheumatic pain seen with willow bark extract STW-33-1

Sep. 9, 2013

Data published from phase II evaluations of a troponin activator in patients with ALS

Sep. 9, 2013

Noninvasive electroencephalograph for functional brain analysis in monkeys

Sep. 9, 2013

Extract from S. scardica shows promise for Alzheimer's disease treatment

Sep. 6, 2013

KemPharm expands pain therapy pipeline with KP-606

Sep. 6, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...